Editas Medicine (EDIT) Shares Outstanding (2015 - 2025)

Editas Medicine (EDIT) has 11 years of Shares Outstanding data on file, last reported at $97.9 million in Q4 2025.

• Shares Outstanding for Q4 2025 came in at $97.9 million, up 18.29% year-over-year; the trailing twelve-month figure through Dec 2025 was $97.9 million (up 18.29% YoY), and the FY2025 annual result was $97.9 million, up 18.29% from the prior year.
• Shares Outstanding climbed to $97.9 million in Q4 2025 per EDIT's latest filing, from $93.3 million in the prior quarter.
• Over five years, Shares Outstanding peaked at $97.9 million in Q4 2025 and troughed at $67.5 million in Q1 2021.
• A 5-year average of $77.7 million and a median of $81.6 million in 2023 frame the typical range for Shares Outstanding.
• The sharpest annual moves came in 2021 and 2023: Shares Outstanding gained 23.12% in 2021, then advanced 0.57% in 2023.
• A 5-year view of Shares Outstanding shows it stood at $68.4 million in 2021, then gained by 0.6% to $68.8 million in 2022, then grew by 18.77% to $81.8 million in 2023, then advanced by 1.18% to $82.7 million in 2024, then gained by 18.29% to $97.9 million in 2025.
• Business Quant data shows EDIT's Shares Outstanding at $97.9 million in Q4 2025, $93.3 million in Q3 2025, and $87.4 million in Q2 2025.